ArticleMalaria journal2025
Mechanism of metabolic resistance in Anopheles coluzzii to insecticides in two urban areas of southern Benin.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Agricultural practices drive multifactorial pyrethroid resistance in Anopheles coluzzii populations from southern Benin.Tropical medicine and health · 2026Article
- Metabolic resistance drives cross-resistance in Aedes albopictus to pyriproxyfen and pyrethroid insecticides.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria is a disease transmitted by the Anopheles gambiae complex, represented mainly in Benin by the sister species An. coluzzii and An. gambiae sensu stricto. Intensive vector control interventions have selected physiological, behavioural and biochemical adaptation mechanisms in these populations of An. vectors. This study aimed to investigate the mechanism of the metabolic resistance of An. coluzzii to insecticides in two urban areas in southern Benin.
methodsLarvae and pupae of An. gambiae s.l. and were collected in the municipalities of Cotonou and Porto-Novo between May and August 2021. The World Health Organization (WHO) sensitivity tests were performed on adult An. gambiae s.l. derived from larvae and pupae. Diagnostic doses of 0.05% deltamethrin, 0.75% permethrin, and 0.1% bendiocarb were used. Species belonging to the An. gambiae complex were identified by PCR, and detoxification enzymes (oxidase, glutathione-S-transferase and esterase) were investigated in An. coluzzii.
resultsThe results showed that An. gambiae s.l. developed resistance to deltamethrin, permethrin and suspected resistance to bendiocarb in the municipalities of Porto-Novo and Cotonou. In addition, the PCR results revealed that An. coluzzii was the predominant species in the municipalities of Cotonou (p < 0.0001) and Porto-Novo (p = 0.002) compared with An. gambiae. Biochemical analysis revealed significantly greater oxidase activity in An. coluzzii in the municipality of Cotonou (p < 0.0001) and low activity in Porto-Novo (p = 0.0958) compared with the susceptible An. coluzzii N'gousso reference strain. Compared with the susceptible An. coluzzii N'gousso reference strain, very high GST activity was detected in the populations of An. coluzzii of Cotonou (p < 0.0001) and Porto-Novo (p = 0.0015). Finally, significantly greater esterase activity (α- and β-esterase) was detected in Porto-Novo than in the susceptible reference strain An. coluzzii N'gousso. Low but not significant esterase activity was also observed in An. coluzzii in Cotonou (p = 0.2120).
conclusionThis study reveals metabolic resistance mechanisms to pyrethroids and carbamates in An. coluzzii populations in the Porto-Novo and Cotonou municipalities. This study confirms the involvement of detoxification enzymes in increased tolerance to these insecticides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.